Last reviewed · How we verify

NCT03790618: ESP

Effect of Stimulant Drugs on Social Perception

Completed Phase 1 Results posted Last updated 5 January 2024
What this trial tests

Phase 1 trial testing 3,4-Methylenedioxymethamphetamine in Healthy in 36 participants. Completed in 1 August 2018.

Timeline
1 June 2016
Primary endpoint
1 August 2018
1 August 2018

Quick facts

Lead sponsorUniversity of Chicago
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposebasic science
Enrollment36
Start date1 June 2016
Primary completion1 August 2018
Estimated completion1 August 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Chicago

Who can join

Adults 18 to 35, any sex, with Healthy or MDMA ('Ecstasy'). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Responses to Affective Touch Primary · End of study (time 0 and approximately six weeks later)

Participants will complete an affective touch task during which time they will rate pleasantness of touch on a likert scale of 1-7, with higher scores indicating greater ratings of pleasantness

GroupValue95% CI
Placebo-1.24± 3.22
Low Dose MDMA0.12± 3.14
High Dose MDMA0.19± 2.25
Methamphetamine0.25± 2.68

Sponsor's own description

The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.
    Kurtz JS, Patel NA, Gendreau JL, Yang C, et al · · 2022 · cited 19× · PMID 36259015 · DOI 10.7759/cureus.29167
  2. MDMA enhances positive affective responses to social feedback.
    Bershad AK, Hsu DT, de Wit H. · · 2024 · cited 7× · PMID 38279662 · DOI 10.1177/02698811231224153

Verify or expand the search:

Other trials of 3,4-Methylenedioxymethamphetamine

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other University of Chicago trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03790618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing